Present More Data On Almitrine, Ifenprodil: CDSCO Panel Tells CDRI-CSIR
New Delhi: After deliberating the Phase III clinical trial protocol of the pulmonary drug Almitrine and Ifenprodil, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the Central Drug Research Institute- Council of Scientific & Industrial Research (CDRI-CSIR) to submit preclinical data, proof of the concept for the...
New Delhi: After deliberating the Phase III clinical trial protocol of the pulmonary drug Almitrine and Ifenprodil, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the Central Drug Research Institute- Council of Scientific & Industrial Research (CDRI-CSIR) to submit preclinical data, proof of the concept for the proposed drugs, the rationale for inclusion/exclusion criteria and the rationale for the proposed study.
This came after the Central Drug Research Institute- Council of Scientific & Industrial Research (CDRI-CSIR) presented the Phase-III clinical trial protocol before the committee.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd